True Wealth Design’s Oric Pharmaceuticals ORIC Stock Holding History

True Wealth Design’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-26	Closed	-$146	–	2755
2025 Q1	$146	Buy	+26	New	+$227	﹤0.01%	2074

Other funds holding ORIC

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

True Wealth Design's ORIC Position: Q2 2025 in Review

True Wealth Design sold out of Oric Pharmaceuticals (ORIC) in Q2 2025, closing a stake of 26 shares — an estimated $146 sold.

True Wealth Design first reported a position in ORIC in Q1 2025 and held it in 1 quarter. The position peaked at $146 in Q1 2025. 142 funds tracked by Wall St. Rank hold ORIC as of Q2 2025.

True Wealth Design reported no remaining Oric Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
True Wealth Design sold 26 Oric Pharmaceuticals shares in Q2 2025, an estimated $146.
True Wealth Design first reported a position in Oric Pharmaceuticals in Q1 2025 and held it in 1 quarter.
True Wealth Design's Oric Pharmaceuticals position peaked at $146 in Q1 2025.
142 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2025.

Based on True Wealth Design's 13F filing for Q2 2025, filed 6 Aug 2025.